Session-Bound Stimulant Use and Fine-Motor Tremor Among 87 Freelance Console Cowboys in Night City and the Eastern Sprawl, 2043–2044

1. Introduction

Among the people who work the matrix for a living, stimulant use is an open and largely unremarked part of the trade. Console cowboys, as the Sprawl calls the operators who jack a deck into cyberspace through dermatrodes and run icebreakers against corporate ICE, describe amphetamine and betaphenethylamine as working tools. Betaphenethylamine is a synthetic phenethylamine derivative with central stimulant action. Respondents value it for sustained alertness with less of the jaw clenching and palpitation they associate with amphetamine (Okabe & Lindqvist, 2036).

Occupational medicine has had little to say about this workforce, and the reason is structural. Much cowboy work is illicit and the people who do it take their medical problems to the black clinics of Chiba City, which operate outside licensed practice (Bandele, 2041). Registry-based case series from those clinics show that systematic record review is feasible there.

The best-known instance of stimulant management in a cowboy is itself a black-clinic procedure. When Case was hired for what became the Straylight run, Chiba surgeons working on his employer's commission replaced his pancreas and modified his liver so that amphetamine and cocaine no longer produced a high. Our account follows a later, anonymised Consortium case report generally taken to describe him (Castellane, 2039). The precedent matters because some cowboys carry metabolic bioware that alters how they handle these drugs.

We asked three questions. How common is stimulant use among working operators, and is current dose strongly graded by duration of use, as it is in recreational users? Is the fine-motor tremor that cowboys describe among themselves associated with drug exposure? And can the timing of that tremor distinguish a drug account from an account based on the deck interface?

2. Methods

Fieldwork ran from the spring of 2043 to the autumn of 2044 in Night City and in the eastern districts of the Sprawl. We recruited through two trusted channels: the Zion Cluster Technical College network, and four Ninsei bar-trade intermediaries who passed contact cards to working operators without reporting who accepted them. Eligibility required at least one paid run in the preceding six months. Of 112 cards distributed, 87 led to a completed interview (77.7%): 49 in Night City and 38 in the Sprawl. Consent was verbal; no names or handles were recorded.

A structured instrument, administered face to face, covered stimulant use in the past twelve months and ever, drug class, per-session dose, years of use, dose timing, weekly hours jacked in, sessions per week with and without stimulants, black-clinic bioware, and fine-motor symptoms. Session-bound dosing was defined as taking stimulants only within the four hours before or during a deck session, with no use on non-working days. Betaphenethylamine doses were converted to amphetamine-equivalent milligrams using a published potency ratio (Okabe & Lindqvist, 2036). Weekly cumulative dose was per-session dose multiplied by dosed sessions per week. The tremor cluster was defined as self-reported hand tremor together with reduced fine dexterity on the keyboard, each present on at least half of working days in the preceding month. Respondents timed onset as on-deck (within the first hour after jacking in), off-deck (between sessions), or mixed. On-deck cases who had run any session without stimulants in that month were asked whether the tremor also appeared on those sessions.

Twenty-two Night City respondents who held accession codes from a Ninsei clinic agreed to linkage. A registry clerk returned coded dosing and tremor fields from their case files (Chiba City Black Clinic Case Registry, 2043–2044). We report percentage agreement and Cohen's κ for each variable (Achterberg, 2042).

The only available population baseline is a public-health series covering working-age adults in the BAMA eastern districts (BAMA Office of Public Health, 2041). No comparable estimate exists for Chiba, so the prevalence comparison was restricted to the 38 Sprawl respondents and tested with an exact binomial test; the baseline's own sampling error was not available and is ignored. Linear regression of current per-session dose on years of use gave a cross-sectional dose–duration gradient, set beside the within-person slope of a longitudinal recreational cohort in the Sprawl (Hollis & Taniguchi, 2038) for context only.

For the binary tremor outcome, we fitted logistic regression among users. Model 1 entered session-bound dosing, dose per session per 10 mg, years of use per five years, weekly deck hours per 10 hours, and pancreatic or hepatic bioware. Model 2 added weekly cumulative dose per 100 mg. The smaller outcome group numbered 31, giving about six non-cases per predictor in Model 1 and five in Model 2, below the conventional threshold, so Model 2 is treated as a sensitivity analysis and all estimates may be somewhat inflated. A further sensitivity analysis excluded bioware carriers. Proportions carry Wilson intervals; the deck-hours and cumulative-dose correlation is a Spearman coefficient.

3. Results

Current use was reported by 81 of 87 respondents (93.1%, 95% CI 85.8–96.8%): 46 of 49 in Night City (93.9%) and 35 of 38 in the Sprawl (92.1%, 95% CI 79.2–97.3%). The Sprawl figure exceeds the 11.8% baseline by 80.3 percentage points (95% CI 67.4–85.5; exact binomial p < .001). Among users, 38 took amphetamine alone (46.9%), 17 betaphenethylamine alone (21.0%) and 26 both (32.1%). Median duration of use was 7 years (IQR 4–11), and 9 users (11.1%) carried pancreatic or hepatic bioware from a black clinic.

Session-bound dosing was reported by 69 of 87 respondents (79.3%, 95% CI 69.6–86.5%), which is 69 of the 81 users (85.2%, 95% CI 75.9–91.3%); the other 12 users also took stimulants on non-working days. For 58 of the 69 session-bound users (84.1%), the usual dose time fell within two hours before jack-in. Current per-session dose was 1.1 mg amphetamine-equivalent higher per additional year of use (95% CI −0.4 to 2.6; p = .15). Even the upper bound sits well below the recreational cohort's within-person slope of 6.8 mg per year (95% CI 5.1–8.5).

Tremor and reduced dexterity were reported by 53 of 87 respondents (60.9%, 95% CI 50.4–70.5%): 50 of the 81 users (61.7%) and 3 of the 6 non-users. Four of the six non-users had used stimulants in earlier years, including two of the three with tremor. By timing, 31 cases (58.5%) had on-deck onset, 9 had off-deck onset and 13 were mixed. Of the 31 on-deck cases, 29 were current users, and 24 of these had run at least one session without stimulants in the preceding month; 17 of the 24 (70.8%, 95% CI 50.8–85.1%) reported the tremor on those sessions as well. The two on-deck non-users, having no dosed sessions, are reported separately; both described tremor on their sessions generally.

In Model 1 (Table 1), each additional 10 hours per week jacked in was associated with higher odds of the tremor cluster (OR 1.84, 95% CI 1.21–2.80, p = .004). No drug-exposure term reached significance, and their intervals were wide. Excluding the 9 bioware carriers changed the deck-hours estimate little (OR 1.79, 95% CI 1.15–2.79). Weekly deck hours and weekly cumulative dose were strongly correlated among users (ρ = 0.68, 95% CI 0.54–0.78). When cumulative dose was added in Model 2, the deck-hours estimate fell to 1.52 (0.88–2.63, p = .13) and cumulative dose itself was imprecise (OR 1.21 per 100 mg, 0.84–1.74, p = .30).

Linkage in the subset of 22 showed agreement on dosing pattern in 19 cases (86.4%, κ = 0.64). For tremor, 14 respondents self-reported the cluster and clinic files documented it for 9 of them, with no documented case among the 8 who denied it; agreement was 17 of 22 (77.3%, κ = 0.57).

4. Discussion

Stimulant use among these operators is near-universal, and for most of them it is tied to the work session. Across users, current dose showed no clear gradient with years of use, and the upper bound of that estimate lies well below the within-person escalation seen in a recreational cohort. The comparison is only indicative (Section 5), but the sampled workforce does not look like a group on a steep escalating course.

The tremor cluster is harder to place, and three accounts remain open. Amphetamine-class stimulants can produce tremor during intoxication (Okabe & Lindqvist, 2036). Because session-bound users dose shortly before jack-in, onset in the first hour on deck coincides with the period of peak drug effect. Intoxication cannot, however, account for tremor on sessions run without any dose, which 17 of the 24 testable on-deck users reported, so it is unlikely to be the whole explanation. Withdrawal is a second candidate. Its recognised picture is dominated by fatigue, low mood and hypersomnia, yet for a regular session-bound user an undosed session is a period of abstinence, and those 17 users are what a withdrawal account would predict as readily as an interface one. The non-user group adds little, since two of its three tremor cases are former users.

A third account concerns the interface itself. Ono-Sendai's engineering notes report a sustained low-level contact current at the electrode sites for the length of a session (Ono-Sendai, 2034). If long exposure to that current affects motor control, it would produce onset at jack-in and a gradient with deck hours. The Model 1 association with deck hours is compatible with that reading, but the model cannot credit it to the interface. Among session-bound users more sessions mean more doses, and once cumulative weekly dose was entered, deck hours and drug load could not be told apart. We offer interface exposure as a hypothesis alongside the two drug accounts. A companion interview study found no association between in-session stimulant use and perceived ICE density, so intoxication does not colour every aspect of on-deck experience, though that finding says nothing about motor function.

Metabolic bioware did not explain the cluster. With nine carriers the null is imprecise, and grafted hepatic and pancreatic tissue follows immunological courses that could alter drug handling over time.

For practice, the defensible recommendations are modest. Black clinics seeing cowboys with tremor should record onset relative to jack-in and to the last dose, since that distinction is what the present records lack. Operators should be told that the cause is unsettled and that reducing stimulant use may not resolve it. A within-operator study with instrumented deck logs, dosing diaries and objective tremor measurement, comparing dosed and undosed sessions, is the next step.

5. Limitations

The sample is self-selected from an illicit population reached through trusted intermediaries. Corporate in-house operators, and those in poor health or under contract secrecy, are likely under-represented. The prevalence estimates therefore describe only the reachable freelance workforce. Survivorship is a particular concern for the dose–duration gradient, since heavy escalators are the operators most likely to have left the workforce.

Exposure and outcome are both self-reported. Clinic records agreed with self-report at κ = 0.64 and 0.57, and every discordant tremor case was an undocumented self-report, which could mean either over-reporting or clinic under-recording; with 22 linked cases, all from Night City, we cannot say which. Dose conversion relies on a single published ratio, and street betaphenethylamine varies in purity.

The population baseline covers the BAMA eastern districts only. It supports a comparison for Sprawl respondents only, and it comes from an earlier year and a different method. The recreational comparator is longitudinal and ours is cross-sectional, so that comparison is contextual. Deck hours are closely tied to cumulative dose, and with 31 non-cases the models cannot separate them. Finally, deck hours and tremor may share an unmeasured cause, and timing depends on one month's recall.